AQNEURSA Approval Signals Oral Suspension Complexity for Rare Disease Manufacturers

IntraBio Ltd's September 2024 FDA approval of AQNEURSA (levacetylleucine) for Niemann-Pick disease, Type C places oral suspension formulation for pediatric rare disease populations squarely on the radar of CDMOs and specialty pharma manufacturers. The approval, covering patients weighing 15 kg or more, requires a formulation deliverable both orally and via G-tube, a dual-route requirement that compounds process validation and sterility assurance considerations under 21 CFR Part 211.

AQNEURSA is indicated to treat the neurological manifestations of NPC in adults and children, administered twice daily as an oral suspension. The G-tube administration pathway introduces additional formulation stability and compatibility requirements that plant heads and QA directors will need to address within their process validation frameworks. As rare disease pipelines increasingly target pediatric populations with complex neurological presentations, the manufacturing infrastructure demands for flexible, low-volume oral liquid dosage forms are intensifying across the sector.

The FDA based its approval on a single randomized, double-blind, placebo-controlled, two-period crossover study of 60 patients conducted across 11 sites in seven countries in Europe and Australia. Patients four years of age or older were randomized 1:1 to receive AQNEURSA or placebo over two 12-week periods. The primary efficacy endpoint was the functional Scale for Assessment and Rating of Ataxia (fSARA), a modified version of the standard SARA instrument incorporating gait, sitting, stance, and speech disturbance domains. Of the 60 enrolled patients, 45 percent were female and 55 percent male, with a median age of 25 years; 90 percent of participants were White, and the age range spanned from 5 to 67 years.

For regulatory affairs leads, the multinational trial design spanning seven countries underscores the ICH Q10 quality system expectations that apply when bridging data from diverse clinical sites into a single regulatory submission. The relatively small trial population, characteristic of orphan disease programs, also highlights the statistical and analytical scrutiny FDA applies when evaluating efficacy signals in limited datasets. Manufacturers entering this space should anticipate close agency engagement on comparability and scale-up protocols as commercial batches move beyond clinical supply volumes.

Source: FDA Drug Trials Snapshots: AQNEURSA, original approval date September 24, 2024. Published April 29, 2026. Available at fda.gov.